Abivax is focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
A clinical-stage company, Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, and is in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease, as well as evaluating other potential inflammatory indications.
We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our drug candidates have the potential to be meaningfully differentiated from currently available therapies.
Abivax leverages technology platforms for drug discovery:
Modulation of RNA Biogenesis: Obefazimod in UC Obefazimod in CD
Based on the mechanistic concept of obefazimod, we have launched a research and development program to generate new potential drug candidates from our proprietary small-molecule library that includes additional miR-124 enhancers.
Abivax’s lead drug candidate, obefazimod, has completed Phase 2a and Phase 2b clinical induction trials, investigating its anti-inflammatory effect and its potential ability to treat adults with moderately to severely active ulcerative colitis (UC), as well as the corresponding follow-on open label extension studies. A Phase 3 clinical trial has been launched. Furthermore, a Phase 2a clinical trial for the treatment of patients with Crohn’s disease is in preparation.